Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 8:44:101103.
doi: 10.1016/j.gore.2022.101103. eCollection 2022 Dec.

Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ovarian cancer

Whitney N Goldsberry  1 , Barbara S Norquist  2 , Rodney P Rocconi  3 , Susan C Modesitt  4 , Renata R Urban  2
Affiliations

Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ovarian cancer

Whitney N Goldsberry et al. Gynecol Oncol Rep. .

Abstract

The Society of Gynecologic Oncology (SGO) Journal Club is an open forum to review pertinent studies relevant to controversial topics in the management of gynecologic cancers. On August 3rd, 2022, SGO hosted a Journal Club focused on the role of maintenance therapy for homologous recombinant proficient (HRP) patients with ovarian cancer. Navigating optimal therapies has become more complex with the emergence of new clinical trial data and the evolving understanding of how to classify ovarian cancers as HRP. Our speakers, Drs. Susan Modesitt, Barbara Norquist and Rodney Rocconi presented Gynecologic Oncology Group (GOG) 218 (Burger et al., 2011), the VITAL Trial (Rocconi et al., 2021), and the PRIMA study (Gonzalez-Martin et al., 2019). We asked our experts to discuss their opinions and interpretations on the application of these data to current clinical practice. Poll questions were presented to the audience for a pre- and post-webinar comparison (Table 1). Results of the poll questions are shown in Table 1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

References

    1. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011 Dec29;365(26):2473-83. 10.1056/NEJMoa1104390. - PubMed
    1. Copeland, L.J., Brady, M.F., Burger, R.A., Rodgers, W.H., Huang, H.Q., Cella, D., O'Malley, D.M., Street, D.G., Tewari, K.S., Bender, D.P., Morris, R.T., Lowery, W.J., Miller, D.S., Dewdney, S.B., Spirtos, N.M., Lele, S.B., Guntupalli, S., Ueland, F.R., Glaser, G.E., Mannel, R.S., DiSaia, P.J., 2022. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J. Clin. Oncol. 2022 Jun 27:JCO2200146. 10.1200/JCO.22.00146. Epub ahead of print. PMID: 35759733. - PMC - PubMed
    1. Frey, M.K., Pothuri, B., 2017. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature Gynecol. Oncol. Res. Pract. 22 (2017) 4:4. 10.1186/s40661-017-0039-8. eCollection 2017.PMID: 28250960. - PMC - PubMed
    1. Gonzalez-Martin A., Pothuri B., Vergote I., DePont C.R., Graybill W., Mirza M.R., McCormick C., Lorusso D., Hoskins P., Freyer G., Baumann K., Jardon K., Redondo A., Moore R.G., Vulsteke C., O’Cearbhaill R.E., Lund B., Backes F., Barretina-Ginesta P., Haggerty A.F., Rubio-Perez M.J., Shahin M.S., Mangili G., Bradley W.H., Bruchim I., Sun K., Malinowska I.A., Li Y., Gupta D., Monk B.J. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962. - DOI - PubMed
    1. Harter P., Mouret-Reynier M.A., Pignata S., Cropet C., González-Martín A., Bogner G., Fujiwara K., Vergote I., Colombo N., Nøttrup T.J., Floquet A., El-Balat A., Scambia G., Guerra Alia E.M., Fabbro M., Schmalfeldt B., Hardy-Bessard A.C., Runnebaum I., Pujade-Lauraine E., Ray-Coquard I. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol. Oncol. 2022;164(2):254–264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22 PMID: 34952708. - DOI - PubMed

LinkOut - more resources